Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: Print Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford : Oxford University Press, [2017]-
    • Subject Terms:
      Health Services Accessibility* ; Ovarian Neoplasms*/mortality ; Ovarian Neoplasms*/therapy; Aged ; Female ; Humans ; Ethnicity ; Medicare ; United States/epidemiology ; Survival Analysis ; Racial Groups ; Health Status Disparities
    • Abstract:
      Background: Racial and ethnic disparities in ovarian cancer (OC) survival are well-documented. However, few studies have investigated how health-care access (HCA) contributes to these disparities.
      Methods: To evaluate the influence of HCA on OC mortality, we analyzed 2008-2015 Surveillance, Epidemiology, and End Results-Medicare data. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between HCA dimensions (affordability, availability, accessibility) and OC-specific and all-cause mortality, adjusting for patient characteristics and treatment receipt.
      Results: The study cohort included 7590 OC patients: 454 (6.0%) Hispanic, 501 (6.6%) Non-Hispanic (NH) Black, and 6635 (87.4%) NH White. Higher affordability (HR = 0.90, 95% CI = 0.87 to 0.94), availability (HR = 0.95, 95% CI = 0.92 to 0.99), and accessibility scores (HR = 0.93, 95% CI = 0.87 to 0.99) were associated with lower risk of OC mortality after adjusting for demographic and clinical factors. Racial disparities were observed after additional adjustment for these HCA dimensions: NH Black patients experienced a 26% higher risk of OC mortality compared with NH White patients (HR = 1.26, 95% CI = 1.11 to 1.43) and a 45% higher risk among patients who survived at least 12 months (HR = 1.45, 95% CI = 1.16 to 1.81).
      Conclusions: HCA dimensions are statistically significantly associated with mortality after OC and explain some, but not all, of the observed racial disparity in survival of patients with OC. Although equalizing access to quality health care remains critical, research on other HCA dimensions is needed to determine additional factors contributing to disparate OC outcomes by race and ethnicity and advance the field toward health equity.
      (© The Author(s) 2023. Published by Oxford University Press.)
    • References:
      J Gen Intern Med. 2007 Mar;22(3):389-95. (PMID: 17356974)
      JNCI Cancer Spectr. 2019 Oct 09;3(4):pkz084. (PMID: 31840133)
      Cancer. 2002 Mar 15;94(6):1886-93. (PMID: 11920552)
      Ann Surg Oncol. 2021 Nov;28(12):7795-7806. (PMID: 33959831)
      Health Expect. 2017 Apr;20(2):321-334. (PMID: 27189772)
      Gynecol Oncol. 2021 Jun;161(3):693-699. (PMID: 33812698)
      JAMA Netw Open. 2023 Feb 1;6(2):e2254595. (PMID: 36723938)
      BMC Health Serv Res. 2013 Jun 11;13:211. (PMID: 23758898)
      Gynecol Oncol. 2015 Jul;138(1):115-20. (PMID: 25922191)
      J Clin Oncol. 2003 Sep 15;21(18):3488-94. (PMID: 12972525)
      Obstet Gynecol. 2013 Nov;122(5):1025-1032. (PMID: 24104782)
      Gynecol Oncol. 2022 Feb;164(2):295-303. (PMID: 34949437)
      J Natl Cancer Inst Monogr. 2020 May 1;2020(55):3-13. (PMID: 32412076)
      Cancer Epidemiol Biomarkers Prev. 2023 Jan 9;32(1):74-81. (PMID: 36306380)
      Gynecol Oncol. 2012 Apr;125(1):19-24. (PMID: 22108636)
      Med Care. 2002 Aug;40(8 Suppl):IV-26-35. (PMID: 12187165)
      Gynecol Oncol. 2015 Jul;138(1):121-7. (PMID: 25913132)
      J Womens Health (Larchmt). 2014 Feb;23(2):138-45. (PMID: 24261647)
      Cancer Epidemiol. 2019 Feb;58:77-82. (PMID: 30528360)
      Obstet Gynecol. 2015 Apr;125(4):833-842. (PMID: 25751200)
      Cancer Epidemiol. 2019 Oct;62:101580. (PMID: 31400533)
      J Clin Oncol. 2005 May 20;23(15):3552-61. (PMID: 15908666)
      J Clin Oncol. 2004 Feb 15;22(4):714-24. (PMID: 14966096)
      Am J Obstet Gynecol. 2015 Apr;212(4):468.e1-9. (PMID: 25448522)
      Clin Cancer Res. 2016 Dec 1;22(23):5909-5914. (PMID: 27521449)
      Ethn Dis. 2001 Autumn;11(3):496-518. (PMID: 11572416)
      Cancer. 2019 Dec 15;125(24):4442-4451. (PMID: 31415710)
      Cancer. 1997 Aug 15;80(4):816-26. (PMID: 9264366)
      Med Care. 2005 Nov;43(11):1130-9. (PMID: 16224307)
      J Natl Cancer Inst. 2013 Jun 5;105(11):823-32. (PMID: 23539755)
      Gynecol Oncol. 2014 Feb;132(2):403-10. (PMID: 24361578)
      Med Care. 1981 Feb;19(2):127-40. (PMID: 7206846)
      Gynecol Oncol. 2014 Jul;134(1):60-7. (PMID: 24680770)
      Gynecol Oncol. 2017 May;145(2):329-333. (PMID: 28215839)
      J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209. (PMID: 24142821)
      Health Equity. 2021 Feb 25;5(1):49-58. (PMID: 33681689)
      Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):539-545. (PMID: 30487136)
      Gynecol Oncol. 2018 Apr;149(1):78-83. (PMID: 29605054)
      Gynecol Oncol. 2021 Jan;160(1):10-15. (PMID: 33208254)
    • Grant Information:
      P30 CA177558 United States CA NCI NIH HHS; R37CA233777 United States CA NCI NIH HHS
    • Publication Date:
      Date Created: 20230216 Date Completed: 20230405 Latest Revision: 20231012
    • Publication Date:
      20240829
    • Accession Number:
      PMC10066801
    • Accession Number:
      10.1093/jncics/pkad011
    • Accession Number:
      36794910